Seres Therapeutics Shareholders Approve Sale of VOWST to Nestlé Health Science

Seres Therapeutics Shareholders Greenlight Sale of VOWST to Nestlé Health Science

In a significant development for Seres Therapeutics, shareholders have approved the sale of VOWST, the company’s experimental microbiome therapeutic product, to Nestlé Health Science. This decision marks a pivotal moment for both organizations as they look to advance research and develop new treatments in the healthcare sector.

The transaction is expected to provide Seres with the necessary resources to further enhance their research capabilities and focus on new therapeutic opportunities. Meanwhile, Nestlé Health Science aims to expand its portfolio in the growing field of microbiome-based therapies, tapping into the increasing demand for innovative health solutions.

Seres Therapeutics expressed gratitude to its shareholders for their support, indicating that the acquisition aligns with their strategic vision and mission to deliver impactful therapies.

As both companies prepare to finalize the transaction, they anticipate that the partnership will facilitate accelerated development and broader accessibility of VOWST and similar products, benefiting patients seeking effective treatment options.

This decision is a crucial step forward for Seres and reflects the ongoing evolution of the healthcare landscape, where collaboration and innovation play key roles in addressing complex medical challenges.